Pediatric exam oriented essays.....on enteric fever, Pediatric TB
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Good. Now let me search for pediatric-specific TB and more detailed enteric fever content.
Finding Sources
Reading File
Finding Sources
Finding Sources
Excellent — Red Book 2021 has dedicated pediatric content on both topics. Let me read the key sections.
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have sufficient content from Red Book 2021 (the authoritative pediatric infectious disease reference) and Harrison's. Let me also quickly grab the TB treatment regimens for disease and the enteric fever clinical manifestations section.
Reading File
Reading File
I now have comprehensive content from the Red Book 2021 for both topics. Let me now compile the exam-oriented essays.---
PEDIATRIC EXAM-ORIENTED ESSAYS
ESSAY 1: ENTERIC FEVER IN CHILDREN
Definition
Enteric fever is a protracted, systemic bacteremic illness caused by Salmonella enterica serovars Typhi (typhoid fever), Paratyphi A, Paratyphi B, and rarely Paratyphi C. Unlike nontyphoidal Salmonella, these serovars infect humans only — there is no animal reservoir.
Etiology
- Gram-negative bacilli, family Enterobacteriaceae
- S. Typhi belongs to O serogroup 9
- Paratyphoid fever is clinically similar but generally milder than typhoid fever
Epidemiology
- Highly endemic in the Indian subcontinent (India, Pakistan, Bangladesh, Nepal), East Africa, and South/Southeast Asia — incidence can exceed 1,000 cases/100,000 children in some urban areas
- In the United States: ~300–400 typhoid and ~100 paratyphoid cases/year; most are travel-acquired
- Peak age: young children and adolescents in endemic areas
- Source: chronic human carriers (mostly biliary infection); contaminated food or water
- Multidrug-resistant (MDR) strains (resistant to chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole) emerged in the 1980s
- XDR (extensively drug-resistant) strains — resistant to all first-line and fluoroquinolones — emerged in Sindh, Pakistan, in 2016 and continue to spread
Pathogenesis
- Ingestion of contaminated food/water → organisms reach small intestine
- Penetrate epithelium via M-cells overlying Peyer's patches
- Enter intestinal lymphatics → bacteremia → dissemination to liver, spleen, gallbladder, bone marrow
- Organisms multiply within intestinal lymphoid tissue, then are re-excreted in stool
- Characteristic pathology: hyperplasia and necrosis of Peyer's patches, focal hepatic necrosis, reticuloendothelial hyperplasia
Clinical Manifestations
Age-based differences (key exam point)
| Feature | Infants & Toddlers | Older Children |
|---|---|---|
| Onset | Mild, nondescript febrile illness OR severe systemic illness | Gradual, insidious |
| Bacteremia | Self-limited or sustained | Sustained |
| Meningitis | Can occur | Rare |
| "Classic" features | Often absent | More common |
Classic features in older children
- Fever: stepwise rise to plateau of 39–40°C
- Constitutional: headache, malaise, anorexia, lethargy
- Abdominal pain, hepatomegaly, splenomegaly
- Rose spots: 1–4 mm blanching pink macules on chest/abdomen (~30% of pediatric patients; <5% in adults with uncomplicated disease)
- Dactylitis (finger swelling — a pediatric feature)
- Relative bradycardia — classically described but not a discriminating feature in children
- Diarrhea ("pea-soup" stool) or constipation — either can be early feature
- GI bleeding in ~10% of hospitalized cases
Complications
- Intestinal hemorrhage and perforation (most feared; was the chief cause of pre-antibiotic mortality)
- Encephalopathy: delirium, obtundation, stupor, coma
- Shock
- Myocarditis, endocarditis (rare)
- Chronic carrier state: >1 year shedding — uncommon in children; more common in adults and females
Diagnosis
Cultures (gold standard)
| Specimen | Sensitivity | Notes |
|---|---|---|
| Blood culture | ~60% | Positive in weeks 1–2 of illness |
| Bone marrow culture | ~90% | Most sensitive; positive even after antibiotics started |
| Bile/duodenal string culture | ~90% (combined with blood) | Practical alternative to bone marrow |
| Stool culture | <30% | Positive from week 2 onward |
| Urine culture | Variable | Less commonly positive |
Serology
- Widal test: NOT recommended by CDC for acute typhoid — difficult to interpret in endemic populations; false positives from prior infection or vaccination
- Commercial immunoassays detecting antibodies to enteric fever antigens: more useful in endemic areas
Molecular
- Multiplex PCR platforms can detect Salmonella directly from stool but culture still required for susceptibility testing
Key lab findings
- Leukopenia (or normal WBC) — in contrast to sepsis where leukocytosis is expected
- Liver enzymes elevated (2–3× ULN)
- Normocytic anemia
Treatment
Susceptibility-guided therapy
| Susceptibility Pattern | Drug of Choice | Duration |
|---|---|---|
| Fully susceptible | Fluoroquinolone (ciprofloxacin) OR amoxicillin OR TMP-SMX | 7–14 days |
| MDR (resistant to chloramphenicol, ampicillin, TMP-SMX) | Third-generation cephalosporin (ceftriaxone/cefotaxime) OR azithromycin | 7–14 days |
| DSC/fluoroquinolone-resistant | Third-generation cephalosporin OR azithromycin | 7–14 days |
| XDR | Azithromycin (oral, uncomplicated) OR carbapenems (severe/IV) | Consult ID |
- Ceftriaxone, cefotaxime, and oral cefixime are effective for MDR enteric fever in adults and children
- Azithromycin is preferred for XDR uncomplicated disease; associated with lower relapse rates than fluoroquinolones or ceftriaxone
- Relapse occurs in up to 17% within 4 weeks; immunocompromised patients require longer treatment
- Corticosteroids (high-dose dexamethasone: 3 mg/kg IV, then 1 mg/kg q6h × 48 h): reserved for severely ill children with delirium, obtundation, stupor, coma, or shock
Chronic carrier treatment
- 4 weeks oral ciprofloxacin or norfloxacin (concentrated in bile)
- Cholecystectomy if antimicrobial therapy fails
Prevention & Vaccines
Two types of typhoid vaccine (licensed in the US)
| Vaccine | Type | Route | Schedule | Min Age | Efficacy | Booster |
|---|---|---|---|---|---|---|
| Ty21a | Live attenuated oral | Oral | Days 1, 3, 5, 7 | 6 years | ~50% at 2.5–3 yr | Every 5 years |
| Vi CPS | Purified Vi polysaccharide | IM | Single dose | 2 years | ~55% at 3 yr | Every 2 years |
- Both poorly immunogenic in children <5 years (T-cell independent response limited)
- Typhoid conjugate vaccines (TCV) — Vi polysaccharide conjugated:
- Typbar TCV (Bharat Biotech, WHO-recommended 2018) and TYPHIBEV (Biological E, 2020)
- Single IM 0.5 mL dose; 79–95% effective; antibody response persisting up to 7 years
- Effective from <2 years of age — superior to unconjugated vaccines
- Now in national immunization programs in Pakistan, Nepal, Zimbabwe, Malawi, and others
Isolation
- Contact precautions for diapered/incontinent children for duration of illness
- Continue until 3 consecutive negative stool cultures ≥48 hours after stopping antibiotics
- For XDR typhoid: contact precautions throughout hospitalization
ESSAY 2: TUBERCULOSIS IN CHILDREN (PEDIATRIC TB)
Definitions (High-Yield)
| Term | Definition |
|---|---|
| TB infection (TBI) / LTBI | M. tuberculosis infection, no symptoms, normal CXR (or healed calcification), positive TST or IGRA |
| TB disease | Active symptomatic illness from M. tuberculosis complex |
| TB exposure | Contact with infectious person; no evidence of infection yet |
| Primary TB | First infection, typically in children |
| Reactivation TB | Adult-pattern cavitary disease from remote infection |
Etiology
- M. tuberculosis complex: M. tuberculosis, M. bovis, M. africanum
- M. bovis: almost universally pyrazinamide-resistant — treatment differs
- Acid-fast bacilli (AFB); slow-growing
- BCG = live attenuated strain of M. bovis
Epidemiology & Transmission
- Transmitted by inhalation of respiratory droplet nuclei from a person with pulmonary/laryngeal TB
- Children are rarely infectious themselves (paucibacillary, poor cough mechanics)
- Incubation: TST/IGRA becomes positive 2–10 weeks after infection (median 3–4 weeks)
- Risk of developing TB disease: highest in first 12 months, remains elevated for 2 years
- High-risk children: age <5 years, immunocompromised (HIV, malnutrition, malignancy, steroids), neonates
Clinical Manifestations
A. Pulmonary TB (most common in children)
- Often asymptomatic (especially TBI)
- When symptomatic: fever, weight loss/poor weight gain, cough, night sweats, chills
- Cavitation uncommon in childhood TB (unlike adults) — exam key point
- Exception: very young, immunocompromised, or lymphobronchial disease
- Chest X-ray features:
- Hilar/mediastinal lymphadenopathy (subcarinal, paratracheal) — most characteristic of primary TB
- Atelectasis or infiltrate (segment or lobe)
- Pleural effusion
- Miliary pattern
- CT/MRI can clarify subtle findings
B. Extrapulmonary TB (children have higher risk than adults)
| Site | Features |
|---|---|
| TB meningitis | Most severe complication; highest risk <5 yr; headache, fever, vomiting, meningism, cranial nerve palsies |
| TB lymphadenitis (scrofula) | Most common extrapulmonary form; firm, non-tender cervical lymphadenopathy |
| TB pericarditis | Constrictive pericarditis risk |
| TB pleuritis | Exudative effusion; lymphocytic |
| TB bones/joints | Spine (Pott's disease), weight-bearing joints |
| Miliary TB | Hematogenous dissemination; high risk in infants and immunocompromised |
| GI TB | Can mimic IBD; M. bovis associated with peritonitis/intestinal obstruction |
| Renal TB | Unusual in young children; adolescents |
| Congenital TB | Mimics neonatal sepsis; bronchopneumonia + hepatosplenomegaly in first 90 days |
Exam key: Children are at greater risk for disseminated and rapidly progressive disease compared to adults. Meningitis and miliary TB are predominantly childhood complications.
Diagnosis
Step 1: Test for M. tuberculosis Infection
Tuberculin Skin Test (TST / Mantoux)
- PPD 5 TU, 0.1 mL intradermal into volar forearm
- Read at 48–72 hours; measure transverse induration in mm
Interpretation (Table 3.74 — Red Book criteria):
| Induration | Positive in |
|---|---|
| ≥5 mm | HIV-infected; recent close TB contact; CXR with old fibrotic changes; immunosuppressed (steroids, anti-TNF); children <5 yr with close contact |
| ≥10 mm | Children <4 yr; those with medical risk factors (diabetes, CKD, malnutrition); born/traveled to high-prevalence countries; exposed to high-risk adults |
| ≥15 mm | Children ≥4 yr with no risk factors |
Causes of false-negative TST in children:
- Young age, malnutrition, immunosuppression
- Viral infections (measles, varicella, influenza) — measles vaccine also suppresses TST up to 4–6 weeks
- Disseminated/severe TB disease (anergy)
- Recent M. tuberculosis infection (<8 weeks)
BCG and TST: BCG can give false positive TST; generally interpret TST in BCG recipients who are known contacts of TB in the same way as non-BCG recipients.
Interferon-Gamma Release Assay (IGRA)
- Measures ex vivo IFN-γ from T lymphocytes stimulated by ESAT-6 and CFP-10 (M. tuberculosis–specific antigens)
- Not affected by BCG (antigens absent from BCG and most NTM — exception: M. kansasii, M. szulgai, M. marinum)
- Preferred over TST in BCG-vaccinated children
- Less reliable in children <2 years (indeterminate results common)
Step 2: Assess for TB Disease
All TST/IGRA-positive children: (1) symptom review, (2) physical exam, (3) chest radiograph
LP in children with TB disease:
- All children <12 months with suspected pulmonary or extrapulmonary TB → LP to rule out TB meningitis
- Children ≥12 months → LP only if neurologic signs/symptoms
Step 3: Bacteriologic Confirmation
- Specimen: sputum (children >2 yr, adolescents); early-morning gastric aspirate × 3 mornings (best specimen for non-productive cough or infants)
- Induced sputum: aerosolized hypertonic saline — feasible even in infants with expertise
- Other specimens: pleural fluid, CSF, lymph node biopsy, bronchial washing, urine
- AFB smear: low sensitivity in children (gastric aspirates); fluorescent staining preferred over Kinyoun
- Culture: gold standard; liquid media + continuous monitoring detects in 1–6 weeks; positive in <75% of infants and <50% of children with pulmonary TB
- NAATs (e.g., Xpert MTB/RIF): increasingly considered confirmatory; detects rifampin resistance simultaneously; culture still required for full susceptibility testing
Treatment
TB Infection (Latent TB) — Treatment Regimens
| Regimen | Drugs | Duration | Age Restriction |
|---|---|---|---|
| 3HP (preferred ≥12 yr) | INH 15 mg/kg (max 900 mg) + Rifapentine (weight-based) | 3 months, weekly | Not for <2 yr |
| 1R (preferred 2–11 yr) | Rifampin 15–20 mg/kg/day (max 600 mg) | 4 months daily | None |
| 3HR | INH + Rifampin daily | 3 months | None (not first-line unless 3HP/4R not feasible) |
| 9H (traditional) | INH 10 mg/kg/day (max 300 mg) | 9 months | None |
All regimens ideally by Directly Observed Therapy (DOT).
TB Disease — First-Line Treatment
Standard regimen (drug-susceptible TB):
- Intensive phase: 2 months of HRZE (Isoniazid + Rifampin + Pyrazinamide + Ethambutol)
- Continuation phase: 4 months of HR (Isoniazid + Rifampin)
- Total: 6 months (standard pulmonary TB)
Extensions:
- If cavities on initial CXR AND sputum culture positive at 2 months → extend continuation phase to 7 months (total 9 months)
- TB meningitis, bone/joint TB, miliary TB: 9–12 months total (longer continuation phase)
- HIV co-infection: may require longer and additional drugs
M. bovis disease: Naturally pyrazinamide-resistant → treat with HRE (no pyrazinamide), typically 9 months
Pediatric drug doses (standard):
| Drug | Dose |
|---|---|
| Isoniazid (H) | 10 mg/kg/day (max 300 mg) |
| Rifampin (R) | 15–20 mg/kg/day (max 600 mg) |
| Pyrazinamide (Z) | 30–40 mg/kg/day (max 2 g) |
| Ethambutol (E) | 15–25 mg/kg/day (max 1 g) |
Note: Pyridoxine (vitamin B6) supplementation with INH for breastfeeding infants, nutritionally deficient children, and those with HIV.
Drug-Resistant TB
- MDR-TB: resistant to at least INH and rifampin → regimen includes fluoroquinolone + injectable aminoglycoside (streptomycin/kanamycin/amikacin) + ethionamide ± PZA — consult ID specialist
- Newer agents: bedaquiline, delamanid (limited pediatric data but increasingly used in MDR-TB)
BCG Vaccine
- Live attenuated M. bovis
- Widely used worldwide; not routinely given in the US
- Highly effective against disseminated TB (miliary TB and TB meningitis) in children — ~80% protection
- Less effective against pulmonary TB in adults
- Contraindicated in severely immunocompromised children (HIV with low CD4) — live vaccine risk
- Cannot be given if untreated TB infection/disease present (initiate anti-TB therapy first)
Prevention & Control
- Contact tracing: all household contacts of an index case must be evaluated
- Source case identification: finding the culture-positive adult source helps guide pediatric treatment
- DOT: cornerstone of all anti-TB therapy
- School/childcare: children generally non-infectious and do not require exclusion once on therapy and improving
- Reporting: mandatory notifiable disease in the US
Summary Comparison Table (Exam High-Yield)
| Feature | Enteric Fever | Pediatric TB |
|---|---|---|
| Organism | S. Typhi / S. Paratyphi (gram-negative) | M. tuberculosis complex (acid-fast bacilli) |
| Transmission | Fecal-oral (contaminated food/water) | Airborne (droplet nuclei) |
| Reservoir | Humans only (chronic carriers) | Humans (rarely animals — M. bovis) |
| Incubation | 7–14 days (range 3–60) | 2–10 weeks (for TST positivity) |
| Key pediatric feature | Dactylitis; rose spots in ~30%; infant presentation can be severe with meningitis | Disseminated/miliary TB + TB meningitis more common in children; cavitation uncommon |
| Gold-standard diagnosis | Blood/bone marrow culture | Culture (sputum/gastric aspirate); NAAT |
| Widal test | Not recommended | Not applicable |
| TST/IGRA | Not applicable | Essential; interpret by risk stratification |
| Treatment duration | 7–14 days | 6–12 months |
| Drug resistance concern | XDR S. Typhi (azithromycin / carbapenem) | MDR-TB (fluoroquinolone + aminoglycoside) |
| Vaccine | TCV (preferred, ≥6 weeks–2 yr); Vi CPS (≥2 yr); Ty21a (≥6 yr) | BCG (protects against miliary TB / meningitis in children) |
Sources: Red Book 2021 (AAP Committee on Infectious Diseases), Harrison's Principles of Internal Medicine 22E (2025), Jawetz Medical Microbiology 28E
---Both essays are complete. Here's a quick orientation to what's covered and what to focus on for exams:
Exam Focus Points
Enteric Fever
- Bone marrow culture (90%) is the most sensitive diagnostic test — frequently asked
- Widal test is not recommended — understand why (false positives, endemic population)
- Rose spots appear in ~30% of children (not <5% as with adults)
- Dactylitis is a pediatric-specific feature
- Relative bradycardia is NOT discriminating in children
- XDR typhoid → azithromycin (oral/uncomplicated) or carbapenems (IV/severe)
- TCV (typhoid conjugate vaccine) is effective from infancy — key advantage over unconjugated vaccines
- Corticosteroids for severe disease: dexamethasone 3 mg/kg IV, then 1 mg/kg q6h × 48 h
Pediatric TB
- Children rarely develop cavitary disease (unlike adults) — a high-yield differentiator
- Children <12 months with any suspected TB → always do LP
- Gastric aspirate × 3 mornings is the specimen of choice in children with non-productive cough
- TST cutoffs: ≥5 mm (high-risk), ≥10 mm (moderate risk), ≥15 mm (low risk)
- BCG does NOT affect IGRA results (ESAT-6/CFP-10 not in BCG)
- M. bovis = always pyrazinamide resistant → treat with HRE only, 9 months
- BCG vaccine protects strongly against miliary TB and TB meningitis in children (~80%)
This is a shared conversation. Sign in to Orris to start your own chat.